ELDN - Company ID 0001404281
The table below shows Eledon Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $18.23M | $17.20M | $14.97M | $20.28M | $13.53M | $16.52M |
| SG&A |
Eledon Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2016. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.64M |
| $3.98M |
| $4.10M |
| $4.46M |
| $4.43M |
| $3.99M |
| Operating income | -$22.87M | -$21.18M | -$19.07M | -$24.73M | -$17.96M | -$20.51M |
| Income tax | - | - | - | - | - | - |
| Net income | -$31.63M | -$39.02M | -$17.46M | -$11.22M | -$6.50M | $76.97M |
| EPS (diluted) | -$0.27 | -$0.33 | -$0.21 | -$0.13 | -$0.08 | -$0.28 |